Ultragenyx Pharmaceutical Inc. buy marge
Start price
19.04.17
/
50%
€58.68
Target price
20.07.17
€63.14
Performance (%)
7.76%
End price
20.07.17
€63.23
Summary
This prediction ended on 20.07.17 with a price of €63.23. With a performance of 7.76%, the BUY prediction by marge for Ultragenyx Pharmaceutical Inc. closed with a slight gain. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.152% | -3.152% | -38.545% | -46.064% |
| iShares Core DAX® | -1.741% | 5.666% | 7.839% | 50.715% |
| iShares Nasdaq 100 | 2.815% | 11.547% | 36.610% | 102.822% |
| iShares Nikkei 225® | -0.109% | 9.654% | 45.650% | 64.795% |
| iShares S&P 500 | 0.966% | 7.240% | 26.969% | 70.251% |
Comments by marge for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical m. Tradingchance on positive results for hypophosphatemia drug test
Ultragenyx Pharmaceutical (NASDAQ:RARE) +19.8% AH on news that its burosumab drug to treat x-linked hypophosphatemia, a genetic kidney disorder, met its primary endpoint in a phase 3 study.
RARE says patients treated with the drug showed a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels vs. 8% on placebo.